BMS Buys IFM Therapeutics for Cancer Pipeline

Aug. 6, 2017

Bristol-Myers Squibb announced the acquisition of IFM Therapeutics, a startup biotech focused on developing therapies that modulate novel targets in the immune system to treat cancer, autoimmunity and inflammatory disorders.

BMS will buy the privately held IFM for an upfront payment of $300 million, gaining access to the company's preclinical cancer programs.

Specifically, the acquisition will give BMS full rights to IFM’s preclinical STING (stimulator of interferon genes) and NLRP3 agonist programs focused on enhancing the innate immune response for treating cancer.

Read the press release